of HIV disease by influencing both parameters that are dependent on viral entry (e.g., viral load) and parameters that are independent of viral entry (e.g., cell-mediated immunity [CMI]) [5] . By contrast, much less is known about the role of the innate immune responses in the pathogenesis of HIV disease. To address this gap in knowledge, in this study we determined whether variations in the gene encoding mannose-binding lectin (MBL), a major component of the innate immune response [6 -9] , influence the risk of HIV acquisition and HIV disease progression rates.
MBL is an evolutionarily conserved, circulating host-defense protein that acts as a broad-spectrum pattern-recognition molecule against a wide variety of infectious agents [7] . MBL mediates its effects by influencing complement activation [8] , opsonization, and phagocytosis [9 -11] . MBL2 contains polymorphisms in the coding and promoter region [12] . The wildtype coding allele is designated the "A allele," whereas the other polymorphisms in the coding sequence (B, C, and D alleles) are collectively designated the "O allele" (figure 1A and 1B) [12] . The variations in the coding sequence affect the structural integrity of MBL, and are associated with a 2-fold to 100-fold reduction in circulating MBL levels [13] . Polymorphisms in the promoter region can also influence MBL levels. For example, the Ϫ221C polymorphism in the MBL2 promoter (designated the "X allele"; figure 1A and 1B) is associated with dramatically lower levels of the structurally intact MBL protein [13] . Thus, variations in MBL2 provide, in part, a genetic basis for the wide range of circulating MBL levels [13, 14] .
In several ethnic groups, there is a high prevalence of polymorphic alleles (e.g., B and C alleles) that result in low MBL levels, which suggests that a relative lack of MBL might be beneficial to the host under some circumstances [15] [16] [17] [18] [19] [20] . This has led Garred et al. and others to hypothesize that these alleles might confer a selective advantage [15] [16] [17] [18] [19] [20] , such as an advantage against infection by intracellular pathogens [21] . An additional proposal is that the high frequencies of the MBL2 polymorphisms that are observed in tropical regions may serve to reduce the detrimental effects of excessive complement activation [15, 22, 23] . Interestingly, although there is an extensive literature demonstrating that variations in MBL2 might alter susceptibility to infectious and noninfectious diseases [7, 12, 24] , only a single report has demonstrated a heterozygous advantage for possession of variations in the coding sequences [25] .
It has been hypothesized that MBL deficiency might also play an important role in the context of coexisting immunodeficiency, such as that of HIV infection [26] . There is strong in vitro data linking MBL to the pathogenesis of HIV disease [26] , and this is based on several observations, including: (1) purified MBL can bind to HIV-infected cell lines and directly inhibit HIV infection of lymphoblasts [27] ; (2) MBL binds to and activates A, MBL2 spans a 3.4-kb area on chromosome 10q11.2-q21 and comprises 4 exons. The positions of the 3 coding polymorphisms (B, C, and D alleles) and the single promoter (Ϫ221) polymorphism studied are shown (reference sequence numbers: codon 52: rs5030737, codon 54: rs1800451, codon 57: rs1800450, and promoter Ϫ221: rs7096206). The 3 coding polymorphisms result in nonsynonymous changes (indicated by arrows, e.g., R52C). The numbers at the top indicate the codon position where the polymorphism occurred. B, Nomenclature used for the MBL2 alleles. The coding alleles B, C and D were analyzed as a single group (the "O allele") [13] . C, Allele and genotype frequency and Hardy-Weinberg equilibrium for the MBL2 alleles and genotypes, by ethnic groups represented in the HIV ϩ cohort. D, Linkage disequilibrium between the promoter and coding region mutations of the MBL2 gene. Linkage disequilibrium was tested by using Lewontin's D' and the 2 test of association. We assessed whether the polymorphisms in the promoter and coding region were in Hardy-Weinberg equilibrium by using the 2 test with 1 degree of freedom. The linkage disequilibrium between promoter and coding polymorphisms was assessed by estimating the normalized disequilibrium parameter (Lewontin's D'). We detected an exception in only 4 individuals who had the XO haplotype (3 African Americans and 1 European American), which indicated that the XO haplotype is extremely infrequent and may represent a rare recombination event.
complement on gp120 [28] ; (3) MBL binds to both CCR5-tropic and CXCR4-tropic primary HIV strains [29] ; and (4) although HIV is relatively resistant to neutralization by MBL, the binding and opsonization of HIV by MBL may alter virus trafficking and viral-antigen presentation during HIV infection [30] . However, despite this extensive in vitro data linking MBL to the pathogenesis of HIV disease, an in vivo link is less clear because the results of genetic epidemiological studies that have investigated the association between variations in MBL2 and HIV-AIDS susceptibility have been inconclusive [14, 26, 31, 32] . Many of these associations were either weak or contradictory and/or were derived mostly from cohorts that involved small sample sizes.
In the present study, we capitalized on a large and wellcharacterized cohort of HIV-1-positive (hereafter, "HIV ϩ ") subjects of European and African descent to test the hypothesis that heterozygosity for polymorphisms in the coding region would result in delayed disease progression rates and possibly afford protection against specific AIDS-defining opportunistic infections. Given the phenotypic effects of the MBL2 promoter X allele on reduction of the levels of the structurally intact MBL protein, in our analyses we also examined the effects of this allele on HIV disease. This was important because most of the prior studies that have examined the HIV disease-influencing effects of variations in MBL2 have been restricted primarily to analyses of structural (coding) mutations, and thus have not accounted for the possible confounding effects of promoter polymorphisms that are in linkage disequilibrium with variations in the coding region [13] . Hence, we reasoned that accounting for this linkage pattern as well as distinguishing between the effects of polymorphisms that result in reduced levels of a structurally intact (promoter variants) versus an unstable protein (variants in coding sequence) might help to clarify the discordant findings regarding the role that variations in MBL2 play in HIV disease. Additionally, we determined whether MBL2 variants affected disease pathogenesis by impacting on the steady-state plasma viral load (VL), a strong predictor of disease progression [5, 33, 34] , as well as delayed-type hypersensitivity (DTH) skin test reactivity, an in vivo marker of CMI [35, 36] that correlates strongly with T cell function in vitro [37, 38] and an independent prognosticator of HIV disease progression [5, 37, 39, 40] . Finally, we assessed whether the disease-influencing effects of MBL2 variants differed on the basis of the genetic context conveyed by CCL3L1-CCR5 genetic risk groups.
PATIENTS, MATERIALS, AND METHODS

Study population.
Adult patients with HIV-1 infection who participated in the US Air Force portion of the Tri-Service AIDS Clinical Consortium Natural History Study contributed samples for this study. Wilford Hall Medical Center (WHMC) is the referral hospital for all US Air Force personnel who develop infection with HIV-1. Extensively detailed descriptions of this cohort have been published elsewhere [3, 5] and additional information is provided in the appendix (which is available only in the electronic edition of the journal).
Genotyping of MBL2 polymorphisms. Complete MBL2 genotyping information was available for 1102 HIV-infected subjects and 2213 subjects not infected with HIV. Genotyping methods are described in the appendix (which is available only in the electronic edition of the journal).
CCL3L1-CCR5 genetic risk groups. Methods for determining the copy number of the CCL3L1 and CCR5 genotypes as well as their categorization into low, moderate, and high CCL3L1-CCR5 genetic risk groups were as described elsewhere [2, 3, 5] .
Delayed type hypersensitivity (DTH) skin test reactivity. The protocols for conducting the DTH skin tests in the HIV ϩ WHMC cohort are as described elsewhere [5, 37, 39] . In brief, each patient, at enrollment and then prospectively, received the standard Mantoux type of intradermal skin test to the following antigens: mumps, Trichophyton, Candida, and tetanus toxoid. Additional details about this parameter and the reasons for using the best DTH response recorded during the course of disease are as described elsewhere [5] and in the appendix (which is available only in the electronic edition of the journal).
Statistical analysis. The statistical procedures used in this paper are described in the appendix (which is available only in the electronic edition of the journal).
RESULTS
Frequency distribution of promoter and coding region alleles.
The distribution pattern of MBL2 alleles in the HIV ϩ WHMC cohort were consistent with those reported elsewhere [22, 41] . The frequencies of the promoter alleles Y (wild type) and X (polymorphic) and the wild-type coding allele A were relatively similar in European American, African American, and Hispanic American subjects ( figure 1A-1C ). By contrast, the frequencies of the polymorphic coding alleles B and C differed significantly among subjects of African and European descent ( figure 1C ). The polymorphic promoter X allele was in nearly complete linkage disequilibrium with the A allele ( figure 1D ) ( 2 ϭ 71.39; P Ͻ .001). On the basis of this linkage pattern, 3 common haplotypes were identified, and in accord with the prevailing nomenclature for MBL2 haplotypes [13] , they were designated the YA, YO, and XA haplotypes. The allele frequencies of the coding and noncoding polymorphisms in MBL2 among HIV ϩ subjects did not deviate significantly from Hardy-Weinberg equilibrium.
Advantage of heterozygosity for MBL2 coding variants. Compared with homozygosity for the A allele (A/A genotype), heterozygosity for the A allele (i.e., A/O genotype) was associated with a significantly slower rate of disease progression ( figure 2A-2C ). Given the link between MBL deficiency and susceptibility to infectious diseases, we determined whether the A/O genotype afforded protection specifically against AIDS-defining opportu- table A2 in the appendix, which is available only in the electronic edition of the journal). In the full regression model, the possession of coding-region heterozygosity was used as the dependent variable and the AIDS-defining illnesses were used as independent variables that were all placed in a single model. Thus, the final stepwise regression model showed the statistically significant association between possession of coding-region heterozygosity and the AIDS-defining illnesses in a multivariate context, an approach that minimized the need for univariate associations and multiple comparisons. The stepwise regression approach used a backward elimination process with a probability criterion of P Ͻ .1. Significant or trending associations (depicted as odds ratio Ϯ confidence intervals) that were close to the significance value of .05 are shown. Coding-region heterozygosity was associated with delayed progression to Pneumocystis jiroveci pneumonia (PCP) (E) and Mycobacterium avium complex (MAC) (F). The association of coding-region heterozygosity with these 2 AIDS-defining illnesses is shown because of the multivariate results shown in D. The reference category in E and F was homozygosity for A/A or O/O. G, H, and I, Kaplan-Meier plots for progression to death based on possession of the Ϫ221 promoter polymorphism in MBL2. The reference category for statistical analysis was the Y/Y genotype. Color-coded numbers under each plot indicate the number of subjects who were at risk at the time points specified on the abscissa. P significance value obtained by Cox proportional hazards regression. "Percentage event-free" refers to the percentage of the cohort who did not die (panels A-C and G-I ) or who did not develop PCP (E) or MAC (F). CI, confidence interval; RH, relative hazards. nistic infections. In a stepwise logistic regression model, a reduced risk (odds) of developing of Pneumocystis jiroveci pneumonia and Mycobacterium avium complex was associated the possession of coding region heterozygosity ( figure 2D ). Additionally, the A/O genotype protected against a rapid rate of progression to P. jiroveci pneumonia and M. avium complex (figure 2E and 2F).
To determine the influence of coding variations on risk of acquiring HIV, we compared the genotype frequencies of MBL2 polymorphisms in 1102 HIV-positive subjects and 2213 subjects not infected with HIV. Possession of the A/O genotype was associated with a trend for a ϳ12% reduction in the risk of acquiring HIV (odds ratio [OR], 0.88 [95% CI, 0.76 -1.03]; P ϭ .110).
Detrimental effects of the X/X promoter genotype on disease. Compared to the Y/Y promoter genotype, possession of the X/X genotype was associated with a rapid rate of disease progression (figure 2G-2I). However, compared with the Y/Y genotype, possession of the X/X genotype was not associated with an increased risk of acquiring HIV (OR, 1.12 [95% CI, 0.77-1.64]; P ϭ .544).
Effects of MBL2 haplotype pairs. Given the aforementioned results, we tested the following 2 hypotheses: (1) because both the A/A and X/X genotypes were each associated with disease-accelerating effects (figure 2A and 2G) and because the polymorphic promoter X allele is in nearly complete linkage with the wild-type coding A allele, the observed diseaseaccelerating effects of the A/A and X/X genotypes are due mainly to the XA/XA haplotype pairs; and (2) based on the genotypephenotype relationships depicted in figure 2A and 2G, MBL2 haplotype pairs that contain the detrimental X/X genotype and the protective A/O genotype will be at the polar ends of the susceptibility spectrum for disease progression rates. To test these hypotheses, we stratified the cohort into 4 MBL2 genotypic groups ( figure 3A) . The findings shown in figure 3B support these 2 hypotheses. Thus, compared with possession of the A/O genotype (group 1, figure 3A) , possession of the XA/XA genotype (group 4, figure 3A) was associated with a nearly 2-fold faster rate of disease progression (figure 3B).
Independent effects of MBL2 polymorphisms on HIV disease. The magnitude of the initial CD4 ϩ T cell loss, steadystate VL, and DTH skin test responses did not differ by MBL2 genotypic group ( figure 3C-3E) . Furthermore, among subjects with a high baseline CD4 ϩ T cell count (figure 3F), low steadystate VL (figure 3G), and robust CMI as characterized by higher numbers of positive DTH skin test results (figure 3H), the MBL2 genotypic groups remained predictors of variable rates of disease progression. Notably, as a general rule, the strength of the association between the MBL2 genotypes and the disease progression rates observed in the cohort overall (figure 3B) was similar or greater in those subjects with favorable laboratory profiles and DTH responses ( figure 3F-3H ). For example, in the cohort overall, the hazard for progression to death for the XA/XA genotype was 2.29 (figure 3B), whereas it was 4.39 (95% CI, 1.84 -10.5), 4.64 (95% CI, 1.73 -12.5), and 2.79 (95% CI, 1.33 -5.85) for those with a CD4 ϩ cell count 700 cells/mm 3 , a VL Ͻ20,000 copies/mL, and 3 positive DTH skin test results, respectively ( figure 3F-3H) .
The aforementioned findings suggested that MBL2 polymorphisms might have independent disease-influencing effects. To assess this possibility further, we determined whether MBL2 genotypes were associated with independent disease-influencing effects after adjustment for parameters that have previously been shown to be independent determinants of disease progression, such as baseline and nadir CD4 ϩ T cell count, steady-state VL, CCL3L1-CCR5 genetic risk groups, and DTH skin test reactivity [5] . Table 1 shows the results of a series of nested Cox proportional hazards models in which we adjusted either separately or in unison for these covariates. The findings indicated that the disease-accelerating effects associated with MBL2 genotypic group 4 (XA/XA) were independent of these parameters (table 1; model 14) (RH ϭ 1.75 [95% CI, 1.00 -3.06]; P ϭ .052).
Permissive CCL3L1-CCR5 genetic environment for the effects of the XA/XA genotype. However, it was not known whether the independent disease-influencing effects of MBL2 genotypes were distributed evenly across the low, moderate, and high CCL3L1-CCR5 genetic risk groups or were restricted to a specific CCL3L1-CCR5 genetic background. This was important to evaluate, as the identification of gene-gene interactions and gene modifiers is a principal challenge for the future understanding of the genetics of non-Mendelian diseases [42, 43] . In a recent study, we found that membership in a low CCL3L1-CCR5 genetic risk group (figure 4A) was associated with high baseline CD4 ϩ T cell counts, low steady-state VL, better delayed-type hypersensitivity skin test responses, and slower rates of disease progression [3, 5] .
In the present study, we found that the disease-accelerating effects associated with the XA/XA genotype were evident in laboratory and delayed-type hypersensitivity profiles that we had previously found to be associated with a low CCL3L1-CCR5 genetic risk group ( figure 3F-3H ). This raised the possibility that the disease-influencing effects of MBL2 genotypes might be restricted to subjects who were members of a low CCL3L1-CCR5 genetic risk group. To test this possibility, we determined the effects of the MBL2 genotypic groups in patients from low, moderate, and high CCL3L1-CCR5 genetic risk groups (figure 4). Among subjects from a low CCL3L1-CCR5 genetic risk group, those who also possessed the MBL2 XA/XA genotype had a 5-fold higher risk of progressing rapidly to death, and this risk increased to 9-fold after adjusting for the baseline CD4 ϩ T cell count and steady-state VL (figure 4B). By contrast, a diseaseaccelerating effect for the MBL2 XA/XA genotype was not evident in subjects from a moderate or high CCL3L1-CCR5 genetic risk group (figure 4B). This suggested that evidence of the disease-influencing effects of MBL2 genotypes may be restricted to a particular CCL3L1-CCR5 genetic background (i.e., a low genetic risk group). Subjects in the WHMC cohort were followed up from the early stages of infection [5] , and the data reported thus far were for all subjects, regardless of seroconversion status. However, the results were consistent even after adjusting for seroconversion status (table A1 in the appendix, which is available only in the electronic edition of the journal). , initial viral load (VL; log 10 copies/mL) and delayed-type hypersensitivity responses (DTH; no. of positive skin test results). The MBL2 genotypic groups stratified subjects with a high baseline CD4 ϩ T cell count (F, 700 cells/mm 3 ), a low initial viral load (G, Ͻ20,000 copies/mL), and robust DTH responses (3 positive skin test results). In panels B, F, G, and H, possession of coding-region heterozygosity was considered the reference category (relative hazard [RH] ϭ 1). Color-coded numbers under each plot indicate the number of subjects who were at risk at the time points specified on the abscissa. P value obtained by Cox proportional hazards regression. 95% CI, 95% confidence interval. We next determined the association between the 4 MBL2 genotypic groups and the rate of progression to AIDS-defining opportunistic illnesses. However, considering the aforementioned results (figure 4), the statistical analyses were restricted to subjects who were also members of a low CCL3L1-CCR5 genetic risk group. In these analyses, the MBL2 genotypic group 1 (i.e., subjects heterozygous for A/O) served as the reference category (RH ϭ 1). Among the subjects who were members of a low CCL3L1-CCR5 genetic risk group, when those with the A/O genotype were compared with subjects who had the other MBL2 genotypic groups, we found the following. First, the MBL2 genotypic groups 2 and 3 were associated with an increased risk of progressing rapidly to Pneumocystis jiroveci pneumonia and HIV-associated dementia, respectively (table A2 in the appendix, which is available only in the electronic edition of the journal). Second, although the relative hazards for progression to specific AIDS-defining illnesses were higher for subjects with the XA/XA genotype (genotypic group 4), compared with those with all other genotypes, they were highest for progression to Kaposi sarcoma and lymphoma (table A2 in the appendix, which is available only in the electronic edition of the journal).
MBL in HIV-AIDS Pathogenesis
DISCUSSION
In the present study, we found that in the context of HIV infection, heterozygosity for polymorphisms that alter the structural integrity of MBL (i.e., the A/O genotype) is associated with disease-retarding effects ( figure 2A-2C) , whereas homozygosity for the promoter X allele-which results in a structurally intact protein but markedly reduced levels of MBL-is associated with disease-accelerating effects ( figure 2G-2I) . These results indicate an important role for MBL2 in the pathogenesis of HIV disease and show that it is not only levels of MBL per se, but also the structural integrity of the MBL protein, that are critical determi- Figure 4 . Disease-influencing effects of MBL2 genotypes on the background of the CCL3L1-CCR5 genetic risk groups. A, Classification schema for the CCL3L1-CCR5 genetic risk groups (GRG). B, Association between MBL2 genotypic groups and HIV disease progression in subjects from the low, moderate, and high CCL3L1-CCR5 genetic risk groups. Color-coding for the MBL2 genotypic groups is as shown in figure 3A . In panel B, the relative hazard (RH) was also adjusted for the baseline CD4 ϩ cell count and steady-state viral load. Color-coded numbers under the Kaplan-Meier plot indicate the number of subjects who were at risk at the time points specified on the abscissa. 
NOTE.
Results are for multivariate Cox proportional hazards modeling of time to death based on the MBL2 genotypic groups before adjustment (model 1) and after adjustment for the indicated covariate(s), either individually (models 2-8) or in unison (models 9 -14). The reference category was subjects in MBL2 genotypic group 1 (A/O heterozygyosity). %CD4 ϩ , percentage of CD4 ϩ T cells; bCD4 ϩ , baseline CD4 ϩ T cell count (cells/mm 3 ); CI, confidence interval; DTH, delayed-type hypersensitivity skin test reactivity; GRG, CCL3L1-CCR5 genetic risk group; n, no. of study subjects; nCD4 ϩ , nadir CD4 ϩ T cell count; T, cohort membership during therapy era; RH, relative hazard; VL, steady-state plasma viral load (log 10 copies/mL). T, DTH, and CCL3L1-CCR5 GRG (low, moderate, and high) are as described elsewhere [5] .
nants of the phenotypic outcomes associated with variations in MBL2. These results also provide support for the hypothesis that heterozygosity for variations in the coding sequence of MBL might provide an advantage against infectious diseases [15] [16] [17] [18] [19] [20] 25] .
The MBL2 genotype-phenotype associations detected offer novel insights into the mechanisms that might mediate HIV disease. We found that variations in MBL2 did not influence the classical determinants of HIV pathogenesis ( figure 3C-3E) and that the effects of these variants on HIV disease were evident among those who had immunologic profiles (high CD4 ϩ count and increased DTH reactivity), virologic profiles (low steadystate VL) and genetic profiles (low CCL3L1-CCR5 genetic risk group) that favored a slow rate of disease progression. These findings indicated that MBL2 genotypes might affect HIV pathogenesis by impacting on distinct pathways that contribute directly to the pathogenesis of specific AIDS-defining illnesses rather than influencing the level of viral replication or CMI as assessed by DTH skin test reactivity. This possibility was affirmed by the fact that the effects associated with MBL2 genotypes remained after adjusting for other established independent determinants of disease progression (table 1) .
The findings shown in figure 4 illustrate 2 points. First, it is important to consider the role of gene-gene interactions in the phenotypic effects associated with genetic variants. Second, the use of only AIDS or death as an end point might mask the effects of genotypes on specific AIDS-defining illnesses. Illustrating the first point, the effects of the XA/XA genotype on the rate of progression to death were most prominent in subjects who belonged to the low CCL3L1-CCR5 genetic risk group. This indicated that specific CCL3L1-CCR5 genotypes provided a permissive genetic environment in which the variants of another gene system, such as MBL2, can fully express their phenotypic effects. Illustrating the second point, even though membership in MBL2 genotypic group 2 or 3 did not influence the overall rate of HIV disease progression among subjects who belonged to the low CCL3L1-CCR5 genetic risk group, these genotypes were associated with more rapid rate of progression to specific AIDS-defining illnesses. The latter findings not only emphasize the range and complexity of the genotype-phenotype relationships but also the importance of accounting for the linkage pattern between polymorphisms in the promoter and coding regions of MBL2.
How might one explain these rather complex effects that MBL has on HIV-AIDS pathogenesis? Because MBL can act both by complement activation and direct opsonization, its net effect in HIV disease is likely to be the result of interplay between these 2 processes. We conjecture that the effect of reduced levels of structurally-impaired versus intact MBL on specific infectious versus noninfectious AIDS-defining illnesses might contribute to the genotype-phenotype relationships detected in this study (discussed in the "Supplementary Note" section of the appendix, which is available only in the electronic edition of the journal). Of interest, recent in vivo studies point to a role for MBL-dependent pathways in malignancy [44 -46] , and whether this underlies the association observed between the XA/XA genotype and lymphoma and Kaposi sarcoma will need validation in other large cohorts that involve subjects with these diseases. However, the failure to detect an association between MBL2 variations and viral load suggests that the direct effects of MBL on HIV replication might be minimal.
Our results differ from those of previous studies that have also examined the association between variations in MBL2 and HIV disease progression [14, 31, 32, 47] . There could be 2 reasons for this. First, these prior studies were limited by moderate or small sample sizes [14, 31, 32, 47] . Second, these studies did not account for the confounding from promoter polymorphisms. One limitation of the present study is that we only used the polymorphism at the Ϫ221 position in the promoter region (X allele). A polymorphism at position Ϫ550 has also been previously studied [48] . However, with respect to these additional polymorphisms, the following points are important to note: the polymorphism at the Ϫ221 position has a more dominant effect on the circulating levels of MBL [13] , and it occurs only when there is a mutation at the Ϫ550 position. The polymorphic allele at Ϫ550 is designated the "L allele" [13] , and these linkage patterns imply that the XA/XA genotype represents the LXA/LXA genotype. Consequently, the genotype-phenotype relationships associated with the XA/XA genotype studied here are also likely to capture the genotype-phenotype relationships associated with the LXA/LXA genotype.
Taken together, our findings provide novel insights into the genetic basis for intersubject differences in the rate of HIV disease progression, because they illustrate the importance of the immune response arm that is linked to MBL during HIV pathogenesis. The findings indicate that variations in the gene that encodes MBL affect HIV pathogenesis without directly impacting previously validated determinants of disease progression, including the extent of viral replication, and their effects might be targeted to specific AIDS-defining illnesses.
APPENDIX PATIENTS, MATERIALS, AND METHODS
Study population. The voluntary, fully informed consent of the subjects used in this research was obtained as required by Air Force Regulation 169 -9 and with approval from the institutional review board of the University of Texas Health Science Center, San Antonio, Texas. A total of 1132 HIV ϩ adult patients were evaluated, including 515 individuals in whom the date of seroconversion could be estimated, as described elsewhere [5] . The ethnic background of this cohort was 55% European American (623 individuals), 36% African American (408 individuals), 6% Hispanic American (69 individuals), and 3% "other" (32 individuals). The median age at the time of diagnosis was 28 years (range, 18 -70 years), and 94% of the subjects (1064 individuals) were male. Forty percent of this cohort (453 individuals) progressed to AIDS (as defined by 1987 criteria), and 39% (442 individuals) died during the study period that ended December 1999. Additional details about this cohort have been published elsewhere [3, 5] .
Genotyping of MBL2 polymorphisms. Complete MBL2 genotyping information was available for 1102 HIV-infected subjects and 2213 subjects not infected with HIV; the latter were similar in age, sex, and ethnic background to the HIV-positive subjects and were also recruited at WHMC. For genotyping of the B and C alleles, we used the same set of primers for polymerase chain reaction (PCR): 5'-GCCTGCACCCAGATTGTAGGA-3' (forward) and 5'-CAGGCAGTTTCCTCTGGAAGG-3' (reverse). The B and C alleles were identified by digesting an aliquot of the PCR product (323 bp) with BanI and MboII restriction enzymes, respectively. For the D allele, the primers were: 5'-CTGTAGCTCTCCAGGCATCAA-CGGCTTCCCAGGCAAAGATGCG-3' (forward) and 5'-TGCT-GACTCCATCTCTTCTTTG-3' (reverse), and the 398-bp PCR fragment was digested with the HhaI restriction enzyme. For the Ϫ221 (X/Y) promoter polymorphism, the primers were 5'-CAATGCACGGTCCCATTTGTTCTCACTGCCGC-3' and 5'-GGACATGGTCCTCACCTTGGTGTGAG-3', and the sense primer created a restriction site for SacII in the PCR amplicon (328 bp) for recognition of the wild-type promoter allele (Y). The restriction endonucleases were obtained from New England Biolabs.
DTH skin test reactivity. DTH responses were denoted as the number of positive skin test results. A total of 1030 (91.47%) subjects had 4 DTH tests, and 96 (8.53%) had 3 tests. Thus for each patient we have several DTH assessments from early-stage disease. The initial DTH response at entry into the cohort and the best DTH response recorded during the course of disease were strong prognosticators of rates of disease progression [5] . However, because subjects had differences in duration of HIV infection at cohort enrollment, the best DTH response was chosen to provide a standardized measure of CMI status. From the time of enrollment into the HIV ϩ WHMC cohort, the median and mean time to the best DTH responses detected during the course of disease was 48 days and 1.34 years (95% confidence interval [CI], 1.19 -1.48 years), respectively. Thus, the best DTH response that we used in our analyses was reflective of early disease [5] . Statistical analysis. Time curves for progression to AIDS (as defined by 1993 criteria), death, and specific AIDS-defining illnesses were plotted using Kaplan-Meier plots. Unadjusted and adjusted relative hazards (RH) were estimated along with their 95% confidence intervals by univariate and multivariate Cox proportional hazards models; the assumption of proportional hazards was tested by using Schoenfeld residuals. We also estimated the risk of acquiring a specific AIDS-defining illness using logistic regression analysis. All the analyses were performed using Stata (version 7.0; Stata). In some instances, similar analyses were conducted in subjects with a high baseline CD4 ϩ T cell count, low steady-state plasma VL, and higher numbers of positive DTH skin test results. The Kruskal-Wallis test was used to determine whether the latter 3 parameters differed by MBL2 genotype.
SUPPLEMENTARY NOTE
We conjecture that a predominant impairment of complement activation might lead to a protective effect against AIDS-related outcomes, whereas a predominant impairment of phagocytic function might exert a detrimental effect on the same outcomes. When both functions are affected, the total effect will depend on the balance of the impairment of these 2 components. These issues are important to consider in the context of this study because polymorphisms in MBL2 result in reduced levels of MBL, but these can be either lower levels of a structurally intact protein (promoter polymorphisms) or an impaired protein (coding mutations). Thus, despite resulting in reduced levels of MBL, MBL2 genotypes might not have the same phenotypic outcome and the final outcome might depend on the balance between the levels of structurally intact and impaired protein. Some of the conceptual basis for this line of reasoning is outlined below. Complement activation might enhance HIV-1 infection. Stoiber et al. [49] surmise that complement activation may culminate in the following 3 possibilities. First, the deposition of C3 fragments might allow HIV to have an effective contact with the complement receptor (CR)-positive and CD4
Ϫ cells, which in turn might result in an enhancement of the infection by augmenting the transfer of HIV. Second, opsonized HIV might directly infect CR-positive cells, such as monocytes, macrophages, and dendritic cells. Third, the terminal complement pathway might be activated to cause virolysis. Given the fact that HIV is known to be only minimally prone to phagocytosis, it is possible that complement activation might help to spread the infection faster. Furthermore, Soelder et al. [50] previously demonstrated that HIV-infected cells have the potential to activate comple-ment, and Gregersen et al. [51] showed that HIV-infected cells are prone to lysis by complement activation. Thus, the activation of the complement pathway might be an event that HIV uses to its advantage [52] . Therefore, we conceptualize that an impairment of complement activation might be advantageous to the host in the context of HIV infection. By contrast, impairment of phagocytic function may have the opposite effect during HIV disease. Kedzierska and Crowe [53] have reviewed the role of the macrophage-monocyte lineage cells in HIV pathogenesis. They argue that a defect in phagocytic function might permit reactivation of opportunistic infections and enhance the morbidity and mortality associated with HIV. Torre et al. [54] also demonstrated that impaired macrophage phagocytosis of polymorphonuclear leucocytic apoptotic bodies may lead to the persistence of an inflammatory state in HIVinfected subjects. Therefore, it is conceivable that an impairment of phagocytic function might facilitate the course of disease in HIV-infected subjects.
In the present study, when considering polymorphisms in the promoter region we observed that the XA/XA genotype was associated with an accelerated disease course. In the light of the published literature, we suggest that in this case the balance of MBL action might be tilted towards impaired phagocytosis without affecting the complement pathway, leading to a detrimental effect.
Heterozygosity in the coding region produces a structurally impaired MBL protein along with reduced levels of circulating MBL [55, 56] . Previous studies have demonstrated that the average level of circulating MBL in subjects heterozygous for the coding region are reduced by a factor of ϳ6-8, compared with wild-type individuals [57, 58] . Although, this is a substantial reduction in circulating levels, we suggest that there is a simultaneous and more dominant impact on complement activation. Consequently, the net effect might be protective. We observed this effect of heterozygosity for MBL2 coding polymorphisms in our analysis.
It may be theoretically possible to build a deterministic model to predict the overall effect of MBL for individual genotypes on the basis of genotype frequencies, serum concentration of MBL, and a quality gradient for the synthesized MBL protein. A recent report [59] also suggests that the ratio between structurally intact and impaired forms of the MBL protein is influenced by the genotype in the coding and promoter region. Thus, the balance between these different forms of MBL might provide the basis for the phenotypic effects observed in the context of reduced serum MBL levels and changes in the structural integrity of MBL protein. 
NOTE.
In these analyses, the MBL2 genotypic group 1 (see figure 3A ) was used as the reference category (relative hazard [RH], 1). Ellipses indicate that results could not be computed for those groups. CMV, cytomegalovirus infection; HAD, HIV-associated dementia; MAC, Mycobacterium avium complex; PCP, Pneumocystis jiroveci pneumonia; PML, progressive multifocal leukoencephalopathy.
